Traductor

02 julio 2017

Right-sided colorectal tumours: an internal radiation advantage

For patients with colorectal cancer that has metastasized to the liver, having a primary tumour on the left side, as opposed to the right side of the colon, is known to be a significant advantage in terms of treatment response.
But now a new study, presented here at the ESMO 19th World Congress on Gastrointestinal Cancer, suggests this imbalance may be at least partially redressed.
Reversing the usual pattern, patients whose liver metastases had spread from right-sided primary tumours (RSP) had a 36% better survival rate after treatment with a combination of first-line chemotherapy and selective internal radiation therapy (SIRT) using Y-90 resin microspheres, compared to chemotherapy alone, according to the study.
This same treatment combination was no better than chemotherapy only in patients with left-sided primary tumours (LSP).

“These findings are good news for patients with right-sided primary tumours, who have a much worse prognosis and fewer treatment options than patients with left-sided tumours,” said study investigator Guy van Hazel, MD, from the University of Western Australia in Perth, Australia.
“We are excited because hitherto no treatment apart from the addition of bevacizumab to chemotherapy has improved the dismal outcome of liver metastases coming from right-sided primary tumours.”
The analysis included 739 patients from two completed studies called SIRFLOX (SF) and FOXFIRE-Global (FFG).
All patients had liver-only or liver-dominant metastatic colorectal cancer (mCRC), and had been randomised to receive either standard chemotherapy alone, or combined with SIRT. The chemotherapy regimen was mFOLFOX6, and most patients received bevacizumab as well.
Information on the patients’ primary tumour location was recorded at the start, with 24% having right-sided and 73% left-sided disease (the remaining 3% had primary tumours on both sides of the colon, or the primary tumour site was unknown).

Overall, outcomes were not different between the chemotherapy alone and chemotherapy plus SIRT groups, with median overall survival (OS) and progression-free survival (PFS) around 24 months and 11 months, respectively.
However, when the investigators examined patients with RSP and LSP separately they saw a clear difference.
Patients with liver metastases from RSP had significantly better OS when SIRT was added to their chemotherapy compared to those who had chemotherapy alone (22.0 vs. 17.1 months, respectively; p=0.007; Hazard Ratio [HR]: 0.64 [95% CI: 0.46-0.89]), but this was not the case for patients with LSP (24.6 vs. 25.6 months; p=0.279; HR: 1.12 [0.92-1.36]).
“That means that RSP patients treated with chemotherapy plus SIRT have a 36% reduced risk of dying at any time point,” said van Hazel.
There was also a 27% improvement in PFS, although this was not statistically significant.
“This is the first time that location of primary tumour has been linked to radiation therapy,” said van Hazel, and although it’s possible that it may only apply to patients receiving first-line therapy, he said it opens a new treatment option for these patients.

There were no differences in side effects between patients with RSP and LSP tumours, and although patients who had both chemotherapy and SIRT did experience more side-effects than those who had chemotherapy alone, these were “predictable and manageable,” said van Hazel.
Commenting on the study, ESMO spokespersons Dirk Arnold, from Instituto CUF de Oncologia in Lisbon, Portugal and Eric Van Cutsem, University Hospitals Leuven, Belgium, said that these findings contribute to the recent debates on both the biological heterogeneity of colon cancers and tumour localisation.
“It remains to be confirmed whether these results mean that right-sided tumours are more sensitive to this kind of radiotherapy – or whether this is simply related to the fact that the molecular characteristics of right-sided tumours allow less treatment options, because they have more mutations,” they explained. “Additionally the well-known worse prognosis of right-sided tumours increases the relative importance of a non-systemic treatment option. More data on the molecular factors determining these results are warranted.”  

1 comentario:

Liam Robert dijo...

Being Herpes is just like been through hell; well special thanks to Dr Imoloa for his powerful Herbal cure for healing me from Herpes disease. I was diagnosed of this disease in the year 2014. Thou I was taking my medications but I was not myself. Until last month My friend came to me and told me that he saw many testimonies on how a great powerful herbal Doctor cured people from Herpes disease. Thou I never believe in Herbal medications, I said to myself seen is believing I took his name and searched it on GOOGLE, I saw many testimonies myself. Quickly, I copied his email I emailed him, And I told him to get the listed items needed to prepare my cure because by then i have little faith in him, few days later he message me that he is through preparing the cure. So he sends it to me through DHL Courier service. I got my parcel, it was a herbal cure as described by Dr. IMOLOA. I took the herbal cure and after taking it for two weeks and some days. He told me to go for check up, I went to the hospital and had a test, and I was cured. Quickly I called him and tell him what happened he congratulated me. I promise to tell the world about him. You should contact dr imoloa today directly at his email address for any type of health problem; lupus disease, mouth ulcer, mouth cancer, body pain, fever, hepatitis ABC, syphilis, diarrhea, HIV / AIDS, Huntington's disease, back acne, chronic kidney failure, addison's disease, chronic pain, Crohn's pain, cystic fibrosis, fibromyalgia, inflammatory Bowel disease, fungal nail disease, Lyme disease, Celia disease, Lymphoma, Major depression, Malignant melanoma, Mania, Melorheostosis, Meniere's disease, Mucopolysaccharidosis, Multiple sclerosis, Muscular dystrophy, Rheumatoid arthritis Alzheimer's disease, parkinson's disease, vaginal cancer, epilepsy Anxiety Disorders, Autoimmune Disease, Back Pain, Back Sprain, Bipolar Disorder, Brain Tumor, Malignant, Bruxism, Bulimia, Cervical Disc Disease, Cardiovascular Disease, Neoplasms , chronic respiratory disease, mental and behavioral disorder, Cystic Fibrosis, Hypertension, Diabetes, Asthma, Autoimmune inflammatory media arthritis ed. chronic kidney disease, inflammatory joint disease, impotence, alcohol spectrum feta, dysthymic disorder, eczema, tuberculosis, chronic fatigue syndrome, constipation, inflammatory bowel disease. You can contact via email - drimolaherbalmamdemedicine@gmail.com/ Whats app+234781986098.Website- http/www.drimolaherbalmademedicine.wordpress.com.

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud